# INTerpath-007 (NCT06295809)

> A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06295809
- Phase: PHASE2, PHASE3
- Status: TERMINATED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Squamous Cell; Skin Neoplasms
- Interventions: Pembrolizumab; Intismeran autogene; Surgery
- Enrollment: 46
- Primary outcome: Event Free Survival (EFS)

## Indexed commentary on INTerpath-007 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=interpath-007-nct06295809